نتائج البحث - David M. Jackman

تنقيح النتائج
  1. 1
    Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

    Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations حسب Elizabeth M Gaughan, Sarah K. Cryer, Beow Y. Yeap, David M. Jackman, Daniel B. Costa

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib

    Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib حسب Stéphanie Héon, Beow Y. Yeap, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors حسب Sarah B. Goldberg, Geoffrey R. Oxnard, Subba R. Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs حسب W. Marston Linehan, Stephanie Cardarella, Christine Lydon, Suzanne E. Dahlberg, David M. Jackman, Pasi A. Jänne, Bruce E. Johnson

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

    Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab حسب Mizuki Nishinoa, Sarah K. Cryer, Yuka Okajim, Lynette M. Sholl, Hiroto Hatabu, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI حسب Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum

    Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum حسب Andrew G. Evans, Christopher A. French, Michael J. Cameron, Christopher D.�M. Fletcher, David M. Jackman, Christopher S. Lathan, Lynette M. Sholl

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival

    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival حسب Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, Tetsuro Araki, Christine Lydon, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Bruce E. Johnson

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer حسب Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors حسب Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC

    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC حسب Raymond H. Mak, Elizabeth Doran, Alona Muzikansky, Josephine Kang, Joel W. Neal, Noah C. Choi, Henning Willers, David M. Jackman, Lecia V. Sequist

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

    Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions حسب Geoffrey R. Oxnard, Peter Lo, Mizuki Nishino, Suzanne E. Dahlberg, Neal I. Lindeman, Mohit Butaney, David M. Jackman, Bruce E. Johnson, Pasi A. Jänne

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

    Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers حسب Kimio Yonesaka, Kreshnik Zejnullahu, Neal I. Lindeman, Alison J. Homes, David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    <i>EGFR</i>Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

    <i>EGFR</i>Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry حسب Lynette M. Sholl, Yun Xiao, Victoria A. Joshi, Beow Y. Yeap, Leigh‐Anne Cioffredi, David M. Jackman, Charles Lee, Pasi A. Jänne, Neal I. Lindeman

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

    Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma حسب David M. Jackman, Hedy L. Kindler, Beow Y. Yeap, Panos Fidias, Ravi Salgia, Joan Lucca, Linda K. Morse, Patricia Ostler, Bruce E. Johnson, Pasi A. Jänne

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

    New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Resp... حسب Mizuki Nishino, David M. Jackman, Hiroto Hatabu, Beow Y. Yeap, Leigh‐Anne Cioffredi, Jeffrey T. Yap, Pasi A. Jänne, Bruce E. Johnson, Annick D. Van den Abbeele

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer حسب David M. Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas J. Lynch, Bruce E. Johnson, Vincent A. Miller

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

    The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations حسب Stéphanie Héon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

    The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer حسب Stephanie Cardarella, Taylor M. Ortiz, Victoria A. Joshi, Mohit Butaney, David M. Jackman, David J. Kwiatkowski, Beow Y. Yeap, Pasi A. Jänne, Neal I. Lindeman, Bruce E. Johnson

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib

    Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib حسب David M. Jackman, Alison J. Holmes, Neal I. Lindeman, Patrick Y. Wen, Santosh Kesari, Ana M. Borras, Christopher J. Bailey, Francisca de Jong, Pasi A. Jänne, Bruce E. Johnson

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: